Cencora Inc banner

Cencora Inc
NYSE:COR

Watchlist Manager
Cencora Inc Logo
Cencora Inc
NYSE:COR
Watchlist
Price: 311.99 USD 0.59% Market Closed
Market Cap: $60.7B

EV/GP

5.6
Current
11%
More Expensive
vs 3-y average of 5.1

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
5.6
=
Enterprise Value
$76.9B
/
Gross Profit
$11.8B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
5.6
=
Enterprise Value
$76.9B
/
Gross Profit
$11.8B

Valuation Scenarios

Cencora Inc is trading above its 3-year average

If EV/GP returns to its 3-Year Average (5.1), the stock would be worth $279.92 (10% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-18%
Maximum Upside
+16%
Average Downside
5%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 5.6 $311.99
0%
3-Year Average 5.1 $279.92
-10%
5-Year Average 4.6 $255.61
-18%
Industry Average 5.2 $285.19
-9%
Country Average 6.5 $360.56
+16%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close

Market Distribution

In line with most companies in the United States of America
Percentile
42nd
Based on 9 428 companies
42nd percentile
5.6
Low
0 — 4.2
Typical Range
4.2 — 10.6
High
10.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 4.2
Median 6.5
70th Percentile 10.6
Max 1 764 211.7

Cencora Inc
Glance View

Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.

COR Intrinsic Value
534.94 USD
Undervaluation 42%
Intrinsic Value
Price $311.99
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett